CAD CAM
Posts (39)
Overview:
textCopy
• Company: Soligenix, Inc. (Ticker: SNGX on NASDAQ)
• Current Stock Price: $4.87 (as of October 3, 2024)
• Valuation: $35.00 per share
• Industry: Med-Biomed/Gene
• Risk Level: HighCompany Focus:
Soligenix is developing a vaccine for Marburg virus called MarVax™. This vaccine is based on Soligenix’s proprietary ThermoVax® technology, which allows for stability at elevated temperatures. It has shown 100% protection in non-human primates and could be a breakthrough if clinical trials are successful.
Recent Events:
textCopy
• An outbreak of Marburg virus in Rwanda has resulted in 26 confirmed cases and 8 deaths.
• Two travelers who had been in Rwanda were hospitalized in Hamburg, Germany with symptoms consistent with the Marburg virus.
• The WHO assessed the risk for Rwanda as “very high” and “high” at the regional level.
• Soligenix’s Marburg vaccine program has gained attention as a result of this outbreak.Financial Overview:
textCopy
• 52-Week High: $15.68
• 52-Week Low: $2.00
• Market Capitalization: $11 million
• Average Daily Volume: 194,874 shares
• Institutional Ownership: 4%
• Insider Ownership: 3%Projected Financials (2023-2026):
textCopy
• The company expects minimal revenues until 2026, with projected earnings losses for the foreseeable future.
• Revenue is mainly derived from grants and contracts, as the company is still in the development stage for most of its products.Outlook and Valuation:
textCopy
• The valuation of $35.00 per share is based on a probability-adjusted discounted cash flow (DCF) model considering potential future revenues from its product pipeline, including HyBryte™, SGX302, and SGX945.
• This valuation is highly contingent upon clinical success and future developments.Summary:
The report emphasizes that the ongoing Marburg outbreak underscores the need for effective vaccines, and Soligenix’s developments position it as a potential key player in this field. The company’s technology offers advantages such as extended stability and high efficacy in non-human primate models.
The research report concludes with a cautiously optimistic outlook, noting that updates on clinical trials and regulatory meetings are expected in the next 12 months.
$CRBP
Someone is right, buying in deep lot of which screenshot says
Guy's who is interested this news, check it out,
Is it useful?
Let me know
$CVKD
$CVKD
Someone was asking before split
?????
Hey @StockTitan
With your great news it will be booom like hell
$NCNC
$BRK-A
Hey richest people come over here and look at those stock, it is definitely should be in your radar!
Here are the top ten companies on NASDAQ with the lowest shares outstanding, listed from lowest to highest:
textCopy
1. Nuwellis Inc. (NASDAQ: NUWE) - 520,000 shares
2. Wheeler Real Estate Investment Trust (NASDAQ: WHLR) - 570,000 shares
3. 1847 Holdings LLC (NASDAQ: EFSH) - 550,000 shares
4. Windtree Therapeutics Inc. (NASDAQ: WINT) - 570,000 shares
5. My Size Inc. (NASDAQ: MYSZ) - 640,000 shares
6. Salarius Pharmaceuticals Inc. (NASDAQ: SLRX) - 600,000 shares
7. Yoshiharu Global Co (NASDAQ: YOSH) - 1,230,000 shares
8. China SXT Pharmaceuticals Inc. (NASDAQ: SXTC) - 730,000 shares
9. Village Bank and Trust Financial Corp (NASDAQ: VBFC) - 1,490,000 shares
10. JW Mays Inc. (NASDAQ: MAYS) - 2,020,000 shares These companies have low float, which can lead to high volatility, making them potentially attractive to day traders.